Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy).

[1]  A. Carter,et al.  The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. , 2008, Journal of the American College of Cardiology.

[2]  M. Bell,et al.  Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction. , 2007, Mayo Clinic proceedings.

[3]  Adelaide,et al.  Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.

[4]  A. Kastrati,et al.  Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. , 2006, JAMA.

[5]  Lippincott Williams Wilkins,et al.  ACC/AHA/SCAI Practice Guidelines, February 21, 2006 , 2006 .

[6]  J. Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.

[7]  E. Antman,et al.  Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. , 2005, JAMA.

[8]  D. Sane,et al.  Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions. , 2004, The Journal of invasive cardiology.

[9]  H. White,et al.  Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. , 2004, American heart journal.

[10]  H. Dauerman,et al.  Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. , 2003, The American journal of cardiology.

[11]  C. Bode,et al.  Abciximab, Eptifibatide, and Tirofiban Exhibit Dose-dependent Potencies to Dissolve Platelet Aggregates , 2003, Journal of cardiovascular pharmacology.

[12]  D. Phillips,et al.  Inhibitory Effects of Glycoprotein IIb/IIIa Antagonists and Aspirin on the Release of Soluble CD40 Ligand During Platelet Stimulation , 2003, Circulation.

[13]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[14]  M. Davidian,et al.  Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes: The COMPARE Trial , 2002, Circulation.

[15]  Samin K. Sharma,et al.  Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study). , 2002, The American journal of cardiology.

[16]  E. Topol,et al.  The TARGET trial: hit or miss? , 2002, European heart journal.

[17]  E. Topol,et al.  Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting: The TARGET Trial* , 2002, Circulation.

[18]  E. Topol,et al.  Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. , 2001, The New England journal of medicine.

[19]  Price Investigators.  Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. , 2001, American heart journal.

[20]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[21]  Marshall A. Lichtman,et al.  Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961 , 2000 .

[22]  D. Kereiakes,et al.  Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. , 1999, The American journal of cardiology.

[23]  T. Investigators.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.

[24]  E. Topol.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.

[25]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.